LXRX Lexicon Pharmaceuticals, Inc.

13.88
+0.04  (0.28%)
Previous Close 13.84
Open 13.86
Price To book 7.78
Market Cap 1.44B
Shares 104,036,000
Volume 495,909
Short Ratio 18.01
Av. Daily Volume 669,100

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17538517
  2. CT ORDER - Confidential treatment order 162060772
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978362
  4. 8-K - Current report 161976678
  5. 8-K - Current report 161963337

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Sotagliflozin
Type 1 Diabetes
PDUFA date under priority review extended by three months to February 28, 2017.
Telotristat etiprate
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Sotagliflozin
Type 2 Diabetes

Latest News

  1. 5 Biotech Stocks You'll Want to Watch in the 1st Quarter
  2. Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
  3. Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference
  4. 7 Key FDA Decisions and Catalysts Expected in January and February
  5. Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint
  6. Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
  7. Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : December 19, 2016
  8. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 16, 2016
  9. Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM)
  10. TherapeuticsMD Soars On Positive Menopause Drug Clinical Trial Results
  11. Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF
  12. 10 Major Pharma and FDA Catalysts Coming in December
  13. Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?
  14. Lexicon Announces the Establishment of the Commercial Leadership Team for Telotristat Ethyl
  15. Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl
  16. LEXICON PHARMACEUTICALS, INC. Financials
  17. ETFs with exposure to Lexicon Pharmaceuticals, Inc. : November 16, 2016
  18. Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
  19. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : November 15, 2016
  20. Lexicon To Present At The Stifel 2016 Healthcare Conference And The Jefferies 2016 Global Healthcare Conference

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17538517
  2. CT ORDER - Confidential treatment order 162060772
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978362
  4. 8-K - Current report 161976678
  5. 8-K - Current report 161963337
  6. 8-K - Current report 161921464
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807451
  8. 8-K - Current report 161805972
  9. CT ORDER - Confidential treatment order 161721535
  10. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 161713510